Patients with chronic hepatitis B virus (HBV) infection in the immune-tolerant phase may still experience hepatic inflammation and disease progression, and could benefit from early antiviral treatment ...
A clinical trial led by Kirby Institute at UNSW Sydney has found that point-of-care testing for hepatitis B DNA is as effective as traditional laboratory testing, paving the way for faster diagnosis ...
New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log ...
As part of their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) can establish an infection in liver cells, researchers led by teams at Memorial Sloan ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Atomic force microscopy images show hepatitis B DNA in its natural state (left) and a zoomed-in look at how it wraps around human histones during an infection (right). The research team determined ...
PBGENE-HBV is designed to potentially cure chronic hepatitis B by eliminating the root cause of the virus. The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an ...
In their effort to answer a decades-old biological question about how the hepatitis B virus (HBV) is able to establish infection of liver cells, researchers have identified a vulnerability that opens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results